Alcon
London – Alcon, the global leader in eye care and a division of Novartis, announces its upcoming presentations, launches and events to take place during the 14th Annual EURETINA Congress in London, starting on September 11.
Retina-related Data Presentations
Among the presentation highlights will be efficacy and safety data for JETREA® (ocriplasmin) based on real-world clinical experience. Two presentations will feature data from single-center studies and one study will provide an evaluation of real-world safety data collected from regulatory authorities around the world. In addition, two new analyses will report on vision-related quality-of-life for patients following treatment with JETREA®, as well as details on the safety profile of the product.
- Ocriplasmin in the Clinical Setting: An Overview of Post-approval Safety Outcomes (Free Paper Session 1; Oral; September 11, 2014; 8:00-10:00 GMT, Auditorium)
- The Time-Course and Resolution of Key Adverse Events in the Ocriplasmin Clinical Trial Programme (Free Paper Session 11; Oral; September 13, 2014; 11:00-13:00 GMT, Boulevard E)
- Clinical Experience with Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: A Single-Centre Case Series (Free Paper Session 11; September 13, 2014; 11:00-13:00 GMT, Auditorium)
- Improved Vision-Related Functionality in Patients with Symptomatic Vitreomacular Adhesion, after Intravitreal Ocriplasmin Injection - Analyses from TG-MV-006 and TG-MV-007 (E-Poster Session)
- A Single-Centre Study with Ocriplasmin in Homogenous Group of Patients with Vitreomacular Traction (E-Poster Session)
- The Impact of Valved and Non-Valved Cannula on Intraoperative Fluid Dynamics and Vitreous (E-Poster Session)